

Patient and Specimen Information


ID 1	EXAMPLE	CCL ID	EXAMPLE
ID 2	EXAMPLE	Collection Date	EXAMPLE
Patient Name	EXAMPLE	Date Received	EXAMPLE
Date of Birth	EXAMPLE	Sample Comments	EXAMPLE

Physician Information

CCL Account No	EXAMPLE	Requesting Physician	EXAMPLE
Clinic/Hospital Name	EXAMPLE		

Patient Results

Gleason Score	aaa	deltaCpIGFBP3	aaa
Tumor Stage	aaa	deltaCpF3	aaa
PSA level (ng/ml)	aaa	deltaCpVGLL3	aaa



Interpretation

The prostate cancer-specific mortality risk at 10 years for a patient with a low P-Score (green, P-score = 0-2) is below 3.4%, for an intermediate P-score (yellow, P-score =3-5) it is below 10.8%, for a high P-score (red, P-score = 6-15) it is above 10.8%

Prostatype is a genetic test that provides survival prognosis and decision support in treatment selection for newly diagnosed prostate cancer patients. Based on gene expression and clinical data of the tested patient the P-score is estimate. The P-score indicates the aggressiveness of the tumour.

References: Peng Z, Skoog L, Hellborg H, et al. Prostate Cancer Prostatic Dis. 2014; 17(1):81-90. Peng Z, Chatzianastasio D, Söderdahl F, et al. Eur Urol Suppl. 2018; 17(2):e161. Read IFU prior to use. for the use only by trained and certified laboratory staff or medical trained and certified health care professionals. This product may only be applied on biopsy from male individuals where a core needle biopsy procedure has confirmed the diagnosis of prostate cancer of Gleason Score 6 or higher. The Prostatype result should always be used in combination with other clinical and patient specific information.

Comments

Approved By: EXAMPLE

Report prepared by: EXAMPLE